{"id":567,"date":"2018-07-19T10:03:02","date_gmt":"2018-07-19T08:03:02","guid":{"rendered":"https:\/\/fci.health\/forschung\/querschnittsprogramme\/"},"modified":"2024-01-05T11:56:56","modified_gmt":"2024-01-05T10:56:56","slug":"clinical-translation-programs","status":"publish","type":"page","link":"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/","title":{"rendered":"Clinical Translation Programs"},"content":{"rendered":"

[vc_row full_width=”stretch_row_content_no_spaces” dhsv_overflow=”vc-overflow-visible”][vc_column][dhsv_vc_header image=”538″ headline=”Clinical Translation Programs”][\/vc_column][\/vc_row][vc_row dhsv_padding_bottom=”vc-padding-bottom-large”][vc_column][vc_empty_space height=”100px”][vc_empty_space height=”25px”][dhsv_vc_forschungsbereiche headtitle=”Research at the FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20centerpiece%20of%20the%20FCI%22%2C%22text%22%3A%22Clinical%20Translation%20Programs%20form%20the%20strategic%20core%20of%20the%20FCI.%20These%20multidisciplinary%20research%20programs%20are%20carried%20out%20by%20interdisciplinary%20teams%20consisting%20of%20researchers%20from%20clinical%20patient%20care%2C%20tumor%20biology%2C%20biochemistry%2C%20chemistry%20and%20bioinformatics.%20The%20respective%20teams%20are%20assembled%20individually%20for%20each%20clinical%20translation%20program.%20Functional%20cancer%20research%20on%20primary%20patient%20material%2C%20preclinical%20and%20clinical%20therapy%20development%20as%20well%20as%20molecular%20profiling%20of%20tumors%20work%20hand-in-hand.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%201%22%2C%22line2%22%3A%22Gastrointestinal%20Tumors%22%2C%22text%22%3A%22Tumor%20response%20to%20neoadjuvant%20radiochemotherapy%20(RCT)%20shows%20a%20wide%20range%20in%20rectal%20cancer%20despite%20identical%20histology%20and%20comparable%20tumor%20stages%2C%20ranging%20from%20clinical%20(cCR)%20and%20histopathological%20complete%20remission%20(pCR)%20to%20tumor%20progression%20and%20metastasis%20under%20therapy.%20Thus%2C%20of%20great%20clinical%20importance%20for%20rectal%20and%20also%20anal%20carcinoma%20is%20to%20(1)%20understand%20the%20molecular%20causes%20of%20heterogeneous%20tumor%20response%20to%20therapy%2C%20and%20(2)%20identify%20potential%20targets%20for%20targeted%20modification%20of%20RCT%20efficacy.%20These%20challenges%20are%20addressed%20here.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%202%22%2C%22line2%22%3A%22Molecular-stratified%20therapy%20of%20acute%20myeloid%20leukemia%22%2C%22text%22%3A%22The%20main%20focus%20of%20the%20program%20is%20on%20two%20major%20aspects%3A%20(1)%20The%20proteogenomic%20characterization%20of%20AML%20to%20explore%20clonal%20heterogeneity%2C%20and%20(2)%20The%20mechanistic%20exploration%20of%20leukemia%20cell%20metabolism%20and%20the%20resulting%20therapeutic%20consequences.%20In%20addition%2C%20we%20will%20include%20immunotherapeutic%20aspects%20in%20the%20program%2C%20which%20are%20currently%20gaining%20increasing%20importance%20in%20AML%20therapy.%20This%20will%20be%20done%2C%20for%20example%2C%20by%20designing%20innovative%20CAR%20immune%20cells%2C%20analyzing%20the%20role%20of%20the%20bone%20marrow%20environment%20on%20immune%20cell-AML%20interaction%2C%20and%20developing%20combinatorial%20treatment%20strategies.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%203%22%2C%22line2%22%3A%22Individualized%20immunotherapeutic%20approaches%20for%20the%20Therapy%20of%20Gliomas%22%2C%22text%22%3A%22The%20overall%20goal%20of%20the%20QP%20is%20to%20further%20develop%20the%20local%20immunotherapeutic%20approaches%20towards%20individualized%20combination%20therapies%2C%20with%20the%20local%20application%20of%20specific%20therapies%20in%20the%20CNS%20or%20tumor%20as%20a%20specific%20focus.%20An%20important%20basis%20for%20this%20is%20the%20in-depth%20characterization%20of%20genetic%2C%20epigenetic%2C%20morphological%20and%20proteomic%20profiles%20of%20tumor%20cells%20and%20surrounding%20cells%20as%20part%20of%20the%20immune%20architecture%20of%20the%20tumor%20in%20close%20cooperation%20with%20the%20newly%20created%20FCI%20platform%20Immunomonitoring.%20The%20mapping%20and%20modeling%20of%20tumor%20evolution%20and%20the%20development%20of%20therapy%20resistance%20by%20bioinformatic%20methods%20and%20the%20further%20development%20and%20increased%20use%20of%20liquid%20biopsies%20represent%20further%20important%20goals%20and%20are%20prerequisites%20for%20the%20rapid%20transfer%20of%20the%20developed%20approaches%20into%20new%20clinical%20trials.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%204%22%2C%22line2%22%3A%22Mechanisms%20of%20the%20metastatic%20cascade%20and%20development%20of%20individualized%20therapeutic%20approaches%22%2C%22text%22%3A%22Metastasis%20represents%20the%20greatest%20overall%20challenge%20in%20oncology%20and%20is%20responsible%20for%20most%20of%20the%20tumor-induced%20mortality.%20Compared%20to%20the%20rapid%20gain%20of%20knowledge%20in%20carcinogenesis%20and%20successful%20therapy%20development%20in%20major%20solid%20tumors%2C%20it%20has%20not%20yet%20been%20possible%20to%20make%20findings%20on%20the%20key%20steps%20of%20the%20metastatic%20cascade%20therapeutically%20useful.%20This%20QP%20aims%20to%20address%20this%20challenge.%20It%20integrates%20projects%20addressing%20(1)%20the%20deciphering%20of%20basic%20mechanisms%20of%20metastasis%20and%20(2)%20the%20development%20of%20experimental%20therapies%20in%20preclinical%20models.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Emerging%20field%22%2C%22line2%22%3A%22Uro-oncology%20(prostate%20and%20bladder%20cancer)%22%2C%22text%22%3A%22In%20addition%20to%20the%20clinical%20translation%20programs%20and%20the%20metastasis%20program%2C%20a%20uro-oncological%20program%20is%20currently%20being%20developed.%20The%20aim%20here%20is%20to%20experimentally%20analyze%20the%20molecular%20and%20cellular%20effects%20of%20the%20genetic%20heterogeneity%20of%20invasive%20bladder%20cancer%20(BC)%20and%20prostate%20cancer%20(PC).%20The%20focus%20of%20the%20program%20is%20on%20the%20analysis%20of%20the%20tumor%20microenvironment%20(TME)%2C%20the%20interactions%20between%20tumor%20and%20non-tumor%20cells%2C%20in%20order%20to%20improve%20the%20prediction%20of%20therapy%20success%2C%20to%20elucidate%20the%20mechanisms%20of%20metastasis%20and%20therapy%20resistance%20and%20to%20develop%20innovative%20therapeutic%20strategies.%22%2C%22color%22%3A%22gray%22%7D%5D”][\/vc_column][\/vc_row][vc_row dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″][dhsv_vc_textwithline expandcontent=”true”]The clinical translation programs form the strategic heart of the FCI. Multidisciplinary teams consisting of clinicians, tumor biologists, biochemists, chemists and bioinformaticians work together in these interdisciplinary research projects. The teams rely on the technology platforms provided by the five research areas. The respective team members are selected individually for each clinical translational program. Functional cancer research on primary patient material, preclinical and clinical therapy development as well as molecular profiling of tumors, work hand in hand.<\/p>\n

The clinical translation programs have their origins in clinical observations and challenges encountered in diagnosis and therapy. They deal with specific diseases or disease groups according to the specialization of the clinical partners.<\/span><\/p>\n

The addressed subjects are consistent with the treatment spectrum of the UCT in order to ensure that clinicians and basic scientists collaborate on issues that arise from the hospital.<\/span>
\nThe clinical translation programs are advertised annually and approved for a period of several years. The progress of the programs is continuously monitored to ensure that they fulfill the essential aims of \u200b\u200bthe FCI.<\/span>[\/dhsv_vc_textwithline][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row full_width=”stretch_row_content_no_spaces” dhsv_overflow=”vc-overflow-visible”][vc_column][dhsv_vc_header image=”538″ headline=”Clinical Translation Programs”][\/vc_column][\/vc_row][vc_row dhsv_padding_bottom=”vc-padding-bottom-large”][vc_column][vc_empty_space height=”100px”][vc_empty_space height=”25px”][dhsv_vc_forschungsbereiche headtitle=”Research at the FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20centerpiece%20of%20the%20FCI%22%2C%22text%22%3A%22Clinical%20Translation%20Programs%20form%20the%20strategic%20core%20of%20the%20FCI.%20These%20multidisciplinary%20research%20programs%20are%20carried%20out%20by%20interdisciplinary%20teams%20consisting%20of%20researchers%20from%20clinical%20patient%20care%2C%20tumor%20biology%2C%20biochemistry%2C%20chemistry%20and%20bioinformatics.%20The%20respective%20teams%20are%20assembled%20individually%20for%20each%20clinical%20translation%20program.%20Functional%20cancer%20research%20on%20primary%20patient%20material%2C%20preclinical%20and%20clinical%20therapy%20development%20as%20well%20as%20molecular%20profiling%20of%20tumors%20work%20hand-in-hand.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%201%22%2C%22line2%22%3A%22Gastrointestinal%20Tumors%22%2C%22text%22%3A%22Tumor%20response%20to%20neoadjuvant%20radiochemotherapy%20(RCT)%20shows%20a%20wide%20range%20in%20rectal%20cancer%20despite%20identical%20histology%20and%20comparable%20tumor%20stages%2C%20ranging%20from%20clinical%20(cCR)%20and%20histopathological%20complete%20remission%20(pCR)%20to%20tumor%20progression%20and%20metastasis%20under%20therapy.%20Thus%2C%20of%20great%20clinical%20importance%20for%20rectal%20and%20also%20anal%20carcinoma%20is%20to%20(1)%20understand%20the%20molecular%20causes%20of%20heterogeneous%20tumor%20response%20to%20therapy%2C%20and%20(2)%20identify%20potential%20targets%20for%20targeted%20modification%20of%20RCT%20efficacy.%20These%20challenges%20are%20addressed%20here.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%202%22%2C%22line2%22%3A%22Molecular-stratified%20therapy%20of%20acute%20myeloid%20leukemia%22%2C%22text%22%3A%22The%20main%20focus%20of%20the%20program%20is%20on%20two%20major%20aspects%3A%20(1)%20The%20proteogenomic%20characterization%20of%20AML%20to%20explore%20clonal%20heterogeneity%2C%20and%20(2)%20The%20mechanistic%20exploration%20of%20leukemia%20cell%20metabolism%20and%20the%20resulting%20therapeutic%20consequences.%20In%20addition%2C%20we%20will%20include%20immunotherapeutic%20aspects%20in%20the%20program%2C%20which%20are%20currently%20gaining%20increasing%20importance%20in%20AML%20therapy.%20This%20will%20be%20done%2C%20for%20example%2C%20by%20designing%20innovative%20CAR%20immune%20cells%2C%20analyzing%20the%20role%20of%20the%20bone%20marrow%20environment%20on%20immune%20cell-AML%20interaction%2C%20and%20developing%20combinatorial%20treatment%20strategies.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%203%22%2C%22line2%22%3A%22Individualized%20immunotherapeutic%20approaches%20for%20the%20Therapy%20of%20Gliomas%22%2C%22text%22%3A%22The%20overall%20goal%20of%20the%20QP%20is%20to%20further%20develop%20the%20local%20immunotherapeutic%20approaches%20towards%20individualized%20combination%20therapies%2C%20with%20the%20local%20application%20of%20specific%20therapies%20in%20the%20CNS%20or%20tumor%20as%20a%20specific%20focus.%20An%20important%20basis%20for%20this%20is%20the%20in-depth%20characterization%20of%20genetic%2C%20epigenetic%2C%20morphological%20and%20proteomic%20profiles%20of%20tumor%20cells%20and%20surrounding%20cells%20as%20part%20of%20the%20immune%20architecture%20of%20the%20tumor%20in%20close%20cooperation%20with%20the%20newly%20created%20FCI%20platform%20Immunomonitoring.%20The%20mapping%20and%20modeling%20of%20tumor%20evolution%20and%20the%20development%20of%20therapy%20resistance%20by%20bioinformatic%20methods%20and%20the%20further%20development%20and%20increased%20use%20of%20liquid%20biopsies%20represent%20further%20important%20goals%20and%20are%20prerequisites%20for%20the%20rapid%20transfer%20of%20the%20developed%20approaches%20into%20new%20clinical%20trials.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%204%22%2C%22line2%22%3A%22Mechanisms%20of%20the%20metastatic%20cascade%20and%20development%20of%20individualized%20therapeutic%20approaches%22%2C%22text%22%3A%22Metastasis%20represents%20the%20greatest%20overall%20challenge%20in%20oncology%20and%20is%20responsible%20for%20most%20of%20the%20tumor-induced%20mortality.%20Compared%20to%20the%20rapid%20gain%20of%20knowledge%20in%20carcinogenesis%20and%20successful%20therapy%20development%20in%20major%20solid%20tumors%2C%20it%20has%20not%20yet%20been%20possible%20to%20make%20findings%20on%20the%20key%20steps%20of%20the%20metastatic%20cascade%20therapeutically%20useful.%20This%20QP%20aims%20to%20address%20this%20challenge.%20It%20integrates%20projects%20addressing%20(1)%20the%20deciphering%20of%20basic%20mechanisms%20of%20metastasis%20and%20(2)%20the%20development%20of%20experimental%20therapies%20in%20preclinical%20models.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Emerging%20field%22%2C%22line2%22%3A%22Uro-oncology%20(prostate%20and%20bladder%20cancer)%22%2C%22text%22%3A%22In%20addition%20to%20the%20clinical%20translation%20programs%20and%20the%20metastasis%20program%2C%20a%20uro-oncological%20program%20is%20currently%20being%20developed.%20The%20aim%20here%20is%20to%20experimentally%20analyze%20the%20molecular%20and%20cellular%20effects%20of%20the%20genetic%20heterogeneity%20of%20invasive%20bladder%20cancer%20(BC)%20and%20prostate%20cancer%20(PC).%20The%20focus%20of%20the%20program%20is%20on%20the%20analysis%20of%20the%20tumor%20microenvironment%20(TME)%2C%20the%20interactions%20between%20tumor%20and%20non-tumor%20cells%2C%20in%20order%20to%20improve%20the%20prediction%20of%20therapy%20success%2C%20to%20elucidate%20the%20mechanisms%20of%20metastasis%20and%20therapy%20resistance%20and%20to%20develop%20innovative%20therapeutic%20strategies.%22%2C%22color%22%3A%22gray%22%7D%5D”][\/vc_column][\/vc_row][vc_row dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″][dhsv_vc_textwithline expandcontent=”true”]The clinical translation programs form the strategic heart of the FCI. Multidisciplinary teams consisting of clinicians, tumor biologists, biochemists, chemists and bioinformaticians work together in these interdisciplinary research projects. The teams rely on the technology platforms provided ganzen Artikel lesen…<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":561,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-567","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nClinical Translation Programs • Frankfurt Cancer Institute<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Translation Programs • Frankfurt Cancer Institute\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=”stretch_row_content_no_spaces” dhsv_overflow=”vc-overflow-visible”][vc_column][dhsv_vc_header image=”538″ headline=”Clinical Translation Programs”][\/vc_column][\/vc_row][vc_row dhsv_padding_bottom=”vc-padding-bottom-large”][vc_column][vc_empty_space height=”100px”][vc_empty_space height=”25px”][dhsv_vc_forschungsbereiche headtitle=”Research at the FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20centerpiece%20of%20the%20FCI%22%2C%22text%22%3A%22Clinical%20Translation%20Programs%20form%20the%20strategic%20core%20of%20the%20FCI.%20These%20multidisciplinary%20research%20programs%20are%20carried%20out%20by%20interdisciplinary%20teams%20consisting%20of%20researchers%20from%20clinical%20patient%20care%2C%20tumor%20biology%2C%20biochemistry%2C%20chemistry%20and%20bioinformatics.%20The%20respective%20teams%20are%20assembled%20individually%20for%20each%20clinical%20translation%20program.%20Functional%20cancer%20research%20on%20primary%20patient%20material%2C%20preclinical%20and%20clinical%20therapy%20development%20as%20well%20as%20molecular%20profiling%20of%20tumors%20work%20hand-in-hand.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%201%22%2C%22line2%22%3A%22Gastrointestinal%20Tumors%22%2C%22text%22%3A%22Tumor%20response%20to%20neoadjuvant%20radiochemotherapy%20(RCT)%20shows%20a%20wide%20range%20in%20rectal%20cancer%20despite%20identical%20histology%20and%20comparable%20tumor%20stages%2C%20ranging%20from%20clinical%20(cCR)%20and%20histopathological%20complete%20remission%20(pCR)%20to%20tumor%20progression%20and%20metastasis%20under%20therapy.%20Thus%2C%20of%20great%20clinical%20importance%20for%20rectal%20and%20also%20anal%20carcinoma%20is%20to%20(1)%20understand%20the%20molecular%20causes%20of%20heterogeneous%20tumor%20response%20to%20therapy%2C%20and%20(2)%20identify%20potential%20targets%20for%20targeted%20modification%20of%20RCT%20efficacy.%20These%20challenges%20are%20addressed%20here.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%202%22%2C%22line2%22%3A%22Molecular-stratified%20therapy%20of%20acute%20myeloid%20leukemia%22%2C%22text%22%3A%22The%20main%20focus%20of%20the%20program%20is%20on%20two%20major%20aspects%3A%20(1)%20The%20proteogenomic%20characterization%20of%20AML%20to%20explore%20clonal%20heterogeneity%2C%20and%20(2)%20The%20mechanistic%20exploration%20of%20leukemia%20cell%20metabolism%20and%20the%20resulting%20therapeutic%20consequences.%20In%20addition%2C%20we%20will%20include%20immunotherapeutic%20aspects%20in%20the%20program%2C%20which%20are%20currently%20gaining%20increasing%20importance%20in%20AML%20therapy.%20This%20will%20be%20done%2C%20for%20example%2C%20by%20designing%20innovative%20CAR%20immune%20cells%2C%20analyzing%20the%20role%20of%20the%20bone%20marrow%20environment%20on%20immune%20cell-AML%20interaction%2C%20and%20developing%20combinatorial%20treatment%20strategies.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%203%22%2C%22line2%22%3A%22Individualized%20immunotherapeutic%20approaches%20for%20the%20Therapy%20of%20Gliomas%22%2C%22text%22%3A%22The%20overall%20goal%20of%20the%20QP%20is%20to%20further%20develop%20the%20local%20immunotherapeutic%20approaches%20towards%20individualized%20combination%20therapies%2C%20with%20the%20local%20application%20of%20specific%20therapies%20in%20the%20CNS%20or%20tumor%20as%20a%20specific%20focus.%20An%20important%20basis%20for%20this%20is%20the%20in-depth%20characterization%20of%20genetic%2C%20epigenetic%2C%20morphological%20and%20proteomic%20profiles%20of%20tumor%20cells%20and%20surrounding%20cells%20as%20part%20of%20the%20immune%20architecture%20of%20the%20tumor%20in%20close%20cooperation%20with%20the%20newly%20created%20FCI%20platform%20Immunomonitoring.%20The%20mapping%20and%20modeling%20of%20tumor%20evolution%20and%20the%20development%20of%20therapy%20resistance%20by%20bioinformatic%20methods%20and%20the%20further%20development%20and%20increased%20use%20of%20liquid%20biopsies%20represent%20further%20important%20goals%20and%20are%20prerequisites%20for%20the%20rapid%20transfer%20of%20the%20developed%20approaches%20into%20new%20clinical%20trials.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%204%22%2C%22line2%22%3A%22Mechanisms%20of%20the%20metastatic%20cascade%20and%20development%20of%20individualized%20therapeutic%20approaches%22%2C%22text%22%3A%22Metastasis%20represents%20the%20greatest%20overall%20challenge%20in%20oncology%20and%20is%20responsible%20for%20most%20of%20the%20tumor-induced%20mortality.%20Compared%20to%20the%20rapid%20gain%20of%20knowledge%20in%20carcinogenesis%20and%20successful%20therapy%20development%20in%20major%20solid%20tumors%2C%20it%20has%20not%20yet%20been%20possible%20to%20make%20findings%20on%20the%20key%20steps%20of%20the%20metastatic%20cascade%20therapeutically%20useful.%20This%20QP%20aims%20to%20address%20this%20challenge.%20It%20integrates%20projects%20addressing%20(1)%20the%20deciphering%20of%20basic%20mechanisms%20of%20metastasis%20and%20(2)%20the%20development%20of%20experimental%20therapies%20in%20preclinical%20models.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Emerging%20field%22%2C%22line2%22%3A%22Uro-oncology%20(prostate%20and%20bladder%20cancer)%22%2C%22text%22%3A%22In%20addition%20to%20the%20clinical%20translation%20programs%20and%20the%20metastasis%20program%2C%20a%20uro-oncological%20program%20is%20currently%20being%20developed.%20The%20aim%20here%20is%20to%20experimentally%20analyze%20the%20molecular%20and%20cellular%20effects%20of%20the%20genetic%20heterogeneity%20of%20invasive%20bladder%20cancer%20(BC)%20and%20prostate%20cancer%20(PC).%20The%20focus%20of%20the%20program%20is%20on%20the%20analysis%20of%20the%20tumor%20microenvironment%20(TME)%2C%20the%20interactions%20between%20tumor%20and%20non-tumor%20cells%2C%20in%20order%20to%20improve%20the%20prediction%20of%20therapy%20success%2C%20to%20elucidate%20the%20mechanisms%20of%20metastasis%20and%20therapy%20resistance%20and%20to%20develop%20innovative%20therapeutic%20strategies.%22%2C%22color%22%3A%22gray%22%7D%5D”][\/vc_column][\/vc_row][vc_row dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″][dhsv_vc_textwithline expandcontent=”true”]The clinical translation programs form the strategic heart of the FCI. Multidisciplinary teams consisting of clinicians, tumor biologists, biochemists, chemists and bioinformaticians work together in these interdisciplinary research projects. The teams rely on the technology platforms provided ganzen Artikel lesen...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Frankfurt Cancer Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-05T10:56:56+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/clinical-translation-programs\\\/\",\"url\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/clinical-translation-programs\\\/\",\"name\":\"Clinical Translation Programs • Frankfurt Cancer Institute\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fci.health\\\/#website\"},\"datePublished\":\"2018-07-19T08:03:02+00:00\",\"dateModified\":\"2024-01-05T10:56:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/clinical-translation-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/clinical-translation-programs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/clinical-translation-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fci.health\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Platform\",\"item\":\"https:\\\/\\\/fci.health\\\/en\\\/platform\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical Translation Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fci.health\\\/#website\",\"url\":\"https:\\\/\\\/fci.health\\\/\",\"name\":\"Frankfurt Cancer Institute\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fci.health\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Translation Programs • Frankfurt Cancer Institute","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Translation Programs • Frankfurt Cancer Institute","og_description":"[vc_row full_width=”stretch_row_content_no_spaces” dhsv_overflow=”vc-overflow-visible”][vc_column][dhsv_vc_header image=”538″ headline=”Clinical Translation Programs”][\/vc_column][\/vc_row][vc_row dhsv_padding_bottom=”vc-padding-bottom-large”][vc_column][vc_empty_space height=”100px”][vc_empty_space height=”25px”][dhsv_vc_forschungsbereiche headtitle=”Research at the FCI” elements=”%5B%7B%22line1%22%3A%22Clinical%20Translation%20Programs%22%2C%22line2%22%3A%22Strategic%20centerpiece%20of%20the%20FCI%22%2C%22text%22%3A%22Clinical%20Translation%20Programs%20form%20the%20strategic%20core%20of%20the%20FCI.%20These%20multidisciplinary%20research%20programs%20are%20carried%20out%20by%20interdisciplinary%20teams%20consisting%20of%20researchers%20from%20clinical%20patient%20care%2C%20tumor%20biology%2C%20biochemistry%2C%20chemistry%20and%20bioinformatics.%20The%20respective%20teams%20are%20assembled%20individually%20for%20each%20clinical%20translation%20program.%20Functional%20cancer%20research%20on%20primary%20patient%20material%2C%20preclinical%20and%20clinical%20therapy%20development%20as%20well%20as%20molecular%20profiling%20of%20tumors%20work%20hand-in-hand.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%201%22%2C%22line2%22%3A%22Gastrointestinal%20Tumors%22%2C%22text%22%3A%22Tumor%20response%20to%20neoadjuvant%20radiochemotherapy%20(RCT)%20shows%20a%20wide%20range%20in%20rectal%20cancer%20despite%20identical%20histology%20and%20comparable%20tumor%20stages%2C%20ranging%20from%20clinical%20(cCR)%20and%20histopathological%20complete%20remission%20(pCR)%20to%20tumor%20progression%20and%20metastasis%20under%20therapy.%20Thus%2C%20of%20great%20clinical%20importance%20for%20rectal%20and%20also%20anal%20carcinoma%20is%20to%20(1)%20understand%20the%20molecular%20causes%20of%20heterogeneous%20tumor%20response%20to%20therapy%2C%20and%20(2)%20identify%20potential%20targets%20for%20targeted%20modification%20of%20RCT%20efficacy.%20These%20challenges%20are%20addressed%20here.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%202%22%2C%22line2%22%3A%22Molecular-stratified%20therapy%20of%20acute%20myeloid%20leukemia%22%2C%22text%22%3A%22The%20main%20focus%20of%20the%20program%20is%20on%20two%20major%20aspects%3A%20(1)%20The%20proteogenomic%20characterization%20of%20AML%20to%20explore%20clonal%20heterogeneity%2C%20and%20(2)%20The%20mechanistic%20exploration%20of%20leukemia%20cell%20metabolism%20and%20the%20resulting%20therapeutic%20consequences.%20In%20addition%2C%20we%20will%20include%20immunotherapeutic%20aspects%20in%20the%20program%2C%20which%20are%20currently%20gaining%20increasing%20importance%20in%20AML%20therapy.%20This%20will%20be%20done%2C%20for%20example%2C%20by%20designing%20innovative%20CAR%20immune%20cells%2C%20analyzing%20the%20role%20of%20the%20bone%20marrow%20environment%20on%20immune%20cell-AML%20interaction%2C%20and%20developing%20combinatorial%20treatment%20strategies.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%203%22%2C%22line2%22%3A%22Individualized%20immunotherapeutic%20approaches%20for%20the%20Therapy%20of%20Gliomas%22%2C%22text%22%3A%22The%20overall%20goal%20of%20the%20QP%20is%20to%20further%20develop%20the%20local%20immunotherapeutic%20approaches%20towards%20individualized%20combination%20therapies%2C%20with%20the%20local%20application%20of%20specific%20therapies%20in%20the%20CNS%20or%20tumor%20as%20a%20specific%20focus.%20An%20important%20basis%20for%20this%20is%20the%20in-depth%20characterization%20of%20genetic%2C%20epigenetic%2C%20morphological%20and%20proteomic%20profiles%20of%20tumor%20cells%20and%20surrounding%20cells%20as%20part%20of%20the%20immune%20architecture%20of%20the%20tumor%20in%20close%20cooperation%20with%20the%20newly%20created%20FCI%20platform%20Immunomonitoring.%20The%20mapping%20and%20modeling%20of%20tumor%20evolution%20and%20the%20development%20of%20therapy%20resistance%20by%20bioinformatic%20methods%20and%20the%20further%20development%20and%20increased%20use%20of%20liquid%20biopsies%20represent%20further%20important%20goals%20and%20are%20prerequisites%20for%20the%20rapid%20transfer%20of%20the%20developed%20approaches%20into%20new%20clinical%20trials.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Clinical%20Translation%20Program%204%22%2C%22line2%22%3A%22Mechanisms%20of%20the%20metastatic%20cascade%20and%20development%20of%20individualized%20therapeutic%20approaches%22%2C%22text%22%3A%22Metastasis%20represents%20the%20greatest%20overall%20challenge%20in%20oncology%20and%20is%20responsible%20for%20most%20of%20the%20tumor-induced%20mortality.%20Compared%20to%20the%20rapid%20gain%20of%20knowledge%20in%20carcinogenesis%20and%20successful%20therapy%20development%20in%20major%20solid%20tumors%2C%20it%20has%20not%20yet%20been%20possible%20to%20make%20findings%20on%20the%20key%20steps%20of%20the%20metastatic%20cascade%20therapeutically%20useful.%20This%20QP%20aims%20to%20address%20this%20challenge.%20It%20integrates%20projects%20addressing%20(1)%20the%20deciphering%20of%20basic%20mechanisms%20of%20metastasis%20and%20(2)%20the%20development%20of%20experimental%20therapies%20in%20preclinical%20models.%22%2C%22link%22%3A%22%7C%7C%7C%22%2C%22color%22%3A%22gray%22%7D%2C%7B%22line1%22%3A%22Emerging%20field%22%2C%22line2%22%3A%22Uro-oncology%20(prostate%20and%20bladder%20cancer)%22%2C%22text%22%3A%22In%20addition%20to%20the%20clinical%20translation%20programs%20and%20the%20metastasis%20program%2C%20a%20uro-oncological%20program%20is%20currently%20being%20developed.%20The%20aim%20here%20is%20to%20experimentally%20analyze%20the%20molecular%20and%20cellular%20effects%20of%20the%20genetic%20heterogeneity%20of%20invasive%20bladder%20cancer%20(BC)%20and%20prostate%20cancer%20(PC).%20The%20focus%20of%20the%20program%20is%20on%20the%20analysis%20of%20the%20tumor%20microenvironment%20(TME)%2C%20the%20interactions%20between%20tumor%20and%20non-tumor%20cells%2C%20in%20order%20to%20improve%20the%20prediction%20of%20therapy%20success%2C%20to%20elucidate%20the%20mechanisms%20of%20metastasis%20and%20therapy%20resistance%20and%20to%20develop%20innovative%20therapeutic%20strategies.%22%2C%22color%22%3A%22gray%22%7D%5D”][\/vc_column][\/vc_row][vc_row dhsv_margin_bottom=”vc-margin-bottom-medium”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″][dhsv_vc_textwithline expandcontent=”true”]The clinical translation programs form the strategic heart of the FCI. Multidisciplinary teams consisting of clinicians, tumor biologists, biochemists, chemists and bioinformaticians work together in these interdisciplinary research projects. The teams rely on the technology platforms provided ganzen Artikel lesen...","og_url":"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/","og_site_name":"Frankfurt Cancer Institute","article_modified_time":"2024-01-05T10:56:56+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/","url":"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/","name":"Clinical Translation Programs • Frankfurt Cancer Institute","isPartOf":{"@id":"https:\/\/fci.health\/#website"},"datePublished":"2018-07-19T08:03:02+00:00","dateModified":"2024-01-05T10:56:56+00:00","breadcrumb":{"@id":"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fci.health\/en\/platform\/clinical-translation-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fci.health\/en\/"},{"@type":"ListItem","position":2,"name":"Platform","item":"https:\/\/fci.health\/en\/platform\/"},{"@type":"ListItem","position":3,"name":"Clinical Translation Programs"}]},{"@type":"WebSite","@id":"https:\/\/fci.health\/#website","url":"https:\/\/fci.health\/","name":"Frankfurt Cancer Institute","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fci.health\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages\/567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/comments?post=567"}],"version-history":[{"count":5,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages\/567\/revisions"}],"predecessor-version":[{"id":3761,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages\/567\/revisions\/3761"}],"up":[{"embeddable":true,"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/pages\/561"}],"wp:attachment":[{"href":"https:\/\/fci.health\/en\/wp-json\/wp\/v2\/media?parent=567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}